Zejula (niraparib) — Cigna

Initial criteria

• Patient age ≥ 18 years
• Patient has BRCA2-altered disease
• Patient has tried one systemic regimen (examples include dacarbazine, docetaxel, doxorubicin, gemcitabine, ifosfamide, or Yondelis [trabectedin intravenous infusion])

Approval duration

1 year